Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05447910
Other study ID # 21-003046
Secondary ID NCI-2022-04802
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 21, 2022
Est. completion date June 15, 2025

Study information

Verified date November 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial examines letrozole in patients with newly diagnosed hormone receptor-positive HER2-negative invasive breast cancer that can be removed by surgery (operable). Letrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some types of breast cancer cells that need estrogen to grow.


Description:

PRIMARY OBJECTIVE: I. To comprehensively evaluate differences in tumor microenvironment subpopulations in aromatase inhibitor (AI)-sensitive versus (vs.) AI-resistant hormone receptor (HR)+ breast cancer. SECONDARY OBJECTIVES: I. To assess the effects of estrogen deprivation on the systemic immune response. II. To assess the effects of estrogen deprivation on tumor immune microenvironment. OUTLINE: Patients receive letrozole orally (PO) once daily (QD) for 2-8 weeks prior to surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo collection of blood and tissue samples.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 15, 2025
Est. primary completion date June 15, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - SCREENING: - Female >= 18 years - Postmenopausal and suitable to receive aromatase inhibitor as per physician's discretion - Histologically confirmed un-resected operable invasive adenocarcinoma of the breast = 0.5 cm with estrogen receptor (ER) and/or progesterone receptor (PR) positive = 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression - Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included - Willing and able to provide research tissue samples - Willing and able to provide research blood samples Exclusion Criteria: - Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive or those on chronic steroids - NOTE: Must be off systemic steroids at least 14 days prior to pre-registration. However, topical steroids, inhalants or steroid eye drops are permitted - Known history of active autoimmune disease that has required systemic treatment within =< 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) prior to pre-registration - NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with Celiac disease controlled with diet modification are not excluded

Study Design


Intervention

Procedure:
Biospecimen Collection
Undergo collection of blood and tissue samples
Drug:
Letrozole
Given PO

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in tumor microenvironment subpopulations in aromatase inhibitor (AI)-sensitive version (vs.) AI-resistant hormone receptor (HR)+ breast cancer Tissue samples from patients with early-stage hormone receptor-positive HER2-negative breast cancer will be collected to compare differences. Up to 8 weeks
Secondary Effects of estrogen deprivation on the immune microenvironment Estrogen receptor will be evaluated by both biopsy and surgical specimens. Up to 8 weeks
Secondary Effects of estrogen deprivation on tumor immune microenvironment Estrogen receptor will be evaluated by both biopsy and surgical specimens. Up to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT04521764 - A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Phase 1
Completed NCT02689427 - Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Phase 2
Terminated NCT00148720 - Capecitabine in Women With Operable Breast Cancer Phase 2
Recruiting NCT05464810 - Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Early Phase 1
Suspended NCT03737695 - Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
Recruiting NCT05406232 - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Withdrawn NCT03238703 - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Phase 4
Completed NCT03679559 - Exercise in Improving Health and Quality of Life in Breast Cancer Survivors N/A
Active, not recruiting NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Phase 2
Active, not recruiting NCT02445391 - Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Phase 3
Completed NCT01964924 - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Phase 2
Recruiting NCT02276443 - Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative N/A
Recruiting NCT05545150 - Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study Phase 2
Active, not recruiting NCT03359954 - Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer Phase 2
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Active, not recruiting NCT05012176 - An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors N/A
Active, not recruiting NCT01334021 - Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer Phase 2
Completed NCT05071677 - Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

External Links